

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER OF PATENTS AND TRADEMARKS PO. Box 1450 Alexandra, Virginia 22313-1450 www.unpto.gov

DATE MAILED: 05/29/2003

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/910,183	07/20/2001	R. A.L. Griffiths	10256.50.3	3168
22913	7590 05/29/2003			
WORKMAN NYDEGGER & SEELEY			EXAMINER	
60 EAST SO	E GATE TOWER UTH TEMPLE		WHISENANT, ETHAN C	
SALILAKE	CITY, UT 84111		ART UNIT	PAPER NUMBER
			1634	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
		09/910,183	GRIFFITHS ET AL.			
Office Action Summary		Examiner	Art Unit			
		Ethan Whisenant, Ph.D.	1634			
Period for	The MAILING DATE of this communicate Reply	ation appears on the cover sheet with	the correspondence address			
THE M - Extens after S - If the p - If NO p - Failure - Any rep	RTENED STATUTORY PERIOD FOR AILING DATE OF THIS COMMUNICATION OF THIS COMMUNICATION OF THIS COMMUNICATION OF THE PROPERTY OF T	ATION. 37 CFR 1.136(a). In no event, however, may a repication. days, a reply within the statutory minimum of thirty (ory period will apply and will expire SIX (6) MONTH, by statute, cause the application to become ABAN	ly be timely filed 30) days will be considered timely. 45 from the mailing date of this communication. NDONED (35 U.S.C. § 133).			
1)⊠	Responsive to communication(s) filed	on <u>24 February 2003</u> .				
2a) <u></u> □	This action is FINAL . 2b)⊠ This action is non-final.				
	Since this application is in condition for closed in accordance with the practice n of Claims					
4)⊠ (Claim(s) <u>1-3,5-11 and 13-18</u> is/are per	nding in the application.				
4.	a) Of the above claim(s) is/are	withdrawn from consideration.				
5)□ (Claim(s) <u>1-3,5-11 and 13-16</u> is/are allo	wed.				
6)⊠ (Claim(s) <u>17 and 18</u> is/are rejected.					
7) 🗌 C	Claim(s) is/are objected to.					
8) 🗌 (Claim(s) are subject to restrictio	n and/or election requirement.				
Applicatio	n Papers					
9)∐ TI	ne specification is objected to by the E	xaminer.				
10)∏ TI	ne drawing(s) filed on is/are: a)	☐ accepted or b)☐ objected to by the	e Examiner.			
	Applicant may not request that any object					
11) 🗌 Th	ne proposed drawing correction filed o	n is: a)□ approved b)□ disa	approved by the Examiner.			
	If approved, corrected drawings are requi	·				
12) Th	ne oath or declaration is objected to by	y the Examiner.				
Priority un	der 35 U.S.C. §§ 119 and 120					
13) X A	cknowledgment is made of a claim fo	r foreign priority under 35 U.S.C. § 1	119(a)-(d) or (f).			
a)⊠	All b) Some * c) None of:					
1	1. Certified copies of the priority documents have been received.					
2	. Certified copies of the priority do	Certified copies of the priority documents have been received in Application No				
	Copies of the certified copies of application from the Internati e the attached detailed Office action for	the priority documents have been re onal Bureau (PCT Rule 17.2(a)). or a list of the certified copies not re	-			
•	knowledgment is made of a claim for o					
a)	The translation of the foreign languknowledgment is made of a claim for	age provisional application has bee	n received.			
Attachment(s			3			
1) Notice	, of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO tion Disclosure Statement(s) (PTO-1449) Pape	-948) 5) Notice of Info	mmary (PTO-413) Paper No(s) prmal Patent Application (PTO-152)			

Art Unit: 1634

DETAILED ACTION

1. The applicant's Response (filed 24 FEB 03) to the Office Action has been entered. Following the entry of the claim amendments, Claim(s) 1-3, 5-11, 13-18 is/are pending. Rejections and/or objections not reiterated from the previous office action are hereby withdrawn. The following rejections and/or objections are either newly applied or reiterated. They constitute the complete set presently being applied to the instant application.

35 USC § 112 - 1ST PARAGRAPH

2. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

CLAIM REJECTIONS under 35 USC § 112-1ST PARAGRAPH

3. Claim(s) 17 is/are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for an isolated allele consisting of any of SEQ ID NOs: 1-36, does not reasonably provide enablement for the entire chromosome on which the allele(s) of the instant invention reside. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected to make the invention commensurate in scope with these claims without undue experimentation.

In *In re Wands*, 858 F.2d 731,737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988) the court considered the issue of enablement in molecular biology. The Court summarized eight factors to be considered in a determination of "undue experimentation". These factors include: (a) the quantity of experimentation necessary; (b) the amount of direction or guidance presented; (c) the presence or absence of working examples; (d) the nature of the invention; (e) the state of the prior art; (f) the relative skill of those in the art; (g) the predictability of the art; and (h) the breadth of the claims. The Court also stated that although the level of skill in molecular biology is high, results of experiments in molecular biology are unpredictable.

To begin, there is no direction or guidance presented as regards the sequence of the entire chromosome (i.e. an isolated allele comprising SEQ ID NOs. 1-36, beyond SEQ ID. NOs: 1-36. While

Application/Control Number: 09/910,183 Page 3

Art Unit: 1634

the relative skill in the art is very high (the Ph.D. degree with laboratory experience), there is no predictability as to what sequences are present on the claimed chromosome(s) beyond that portion of the chromosome consisting of SEQ ID NOs: 1-36.

The specification provides numerous working examples (i.e. SEQ ID NOs: 1-36). Finally, as regards the nature of the invention, the claimed invention is drawn to polynucleotides. Polynucleotides area chemical compound with an exact nucleotide sequence and claims drawn to polynucleotides should clearly define the nucleotide sequence for which protection is desired. The breadth of these claims includes any polynucleotide sequence - including an entire human chromosome - which comprises any of SEQ ID NOs: 1-36. Accordingly, it is concluded that undue experimentation is required to make the invention as it is claimed. See M.P.E.P. §§ 706.03(n) and 706.03(z).

35 USC § 112- 2ND PARAGRAPH

4. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

CLAIM REJECTIONS under 35 USC § 112- 2ND PARAGRAPH

5. Claim(s) 18 is/are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 18 is indefinite because it is unclear what is intended by the words/phrases "D21511" and "D18551". These appear to be typographical errors which should read "D21S11" and "D18S51". Please clarify.

Art Unit: 1634

35 USC § 102

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that may form the basis for rejections set forth in this Office action:

A person shall be entitled to a patent unless --

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) The invention was described in -
- (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effect under this subsection of a national application published under section 122(b) only if the international application designating the United States was published under Article 21(2)(a) of such treaty in the English language; or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that a patent shall not be deemed filed in the United States for the purposes of this subsection based on the filing of an international application filed under the treaty defined in section 351(a)

CLAIM REJECTIONS UNDER 35 USC § 102

7. Claim(s) 17 is/are rejected under 35 U.S.C. 102(b) as being anticipated by Barber et al. (1996).

Claim 17 is drawn to an isolated allele comprising or consisting of a sequence selected from a defined group which includes (AGAA)₈.

Barber et al. teach an isolated allele comprising the sequence (AGAA)₈. For example, see any of the alleles shown in Figure 2 on page 64. Note, for example, the column entitled "Repeat Sequence" teaches isolated allele no. 9 which has the structure (AGAA)₉ which is an isolated allele comprising the sequence (AGAA)₈.

Application/Control Number: 09/910,183

Art Unit: 1634

35 USC § 103

Page 5

8. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

9. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. § 103, the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligations under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of potential 35 U.S.C. § 102(f) or (g) prior art under 35 U.S.C. § 103.

CLAIM REJECTIONS UNDER 35 USC § 103

10. Claim(s) 18 is/are rejected under 35 U.S.C. 103(a) as being unpatentable over Barber et al.(1996) as applied against Claim 17 above and further in view of Schumm et al. [US 5,559,666 (1997)].

Claim 18 is drawn to an embodiment of Claim 17 wherein one or more of the alleles of Claim 17 are provided purified from alleles other than those of HUMVWFA31/A, HUMTH01, D18S1179, HUMFIBRA/FGA, D21511 (i.e. D21S11?), D18551 (i.e. D18S51?) or AMG loci

Barber et al. teach all of the limitations of Claim 18 except these authors do not explicitly teach providing one or more of the alleles of Claim 17 in a purified form except that the one or more of the alleles of Claim 17 may comprise other alleles selected from the group consisting of HUMVWFA31/A, HUMTH01, D18S1179, HUMFIBRA/FGA, D21511 (i.e. D21S11?), D18551 (i.e. D18S51?) and AMG loci. However, Schumm et al. do teach allelic ladders and kits thereof. Therefore, absent an unexpected result, it would have been *prima facie* obvious to the ordinary artisan at the time of the invention to provide all of the alleles (i.e. alleles 9-27) for D18S51 in purified form (i.e. in a kit format) in order to more easily and accurately analyze the results of an assay involving D18S51 amplification.

Application/Control Number: 09/910,183 Page 6

Art Unit: 1634

RESPONSE TO APPLICANT'S AMENDMENT/ ARGUMENTS

11. Applicant's arguments with respect to the claimed invention have been fully and carefully considered but are moot in view of the new ground(s) of rejection.

CONCLUSION

- 12. Claim(s) 1-3, 5-11, 13-16 is/are allowable while Claim(s) 17-18 is/are rejected and/or objected to for the reason(s) set forth above.
- **13.** Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ethan Whisenant, Ph.D. whose telephone number is (703) 308-6567. The examiner can normally be reached Monday-Friday from 8:30AM -5:30PM EST or any time via voice mail. If repeated attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones, can be reached at (703) 308-1152.

The fax number for this Examiner is (703) 746-8465. Before faxing any papers please inform the examiner to avoid lost papers. Please note that the faxing of papers must conform with the Notice to Comply published in the Official Gazette, 1096 OG 30 (November 15, 1989). Any inquiry of a general nature or relating to the status of this application should be directed to the group receptionist whose telephone number is (703) 308-0196.

ETHAN WHISENANT PRIMARY EXAMINER